– CANADA, Mississauga – Profound Medical Corp. (TSX: PRN | OTCQX: PRFMF), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced the appointment of Steve Forte to its Board of Directors. The appointment of Steve Forte, who will serve on the Board’s Audit Committee, increases the size of the Board to seven members.
“On behalf of everyone at Profound, I am very pleased to welcome Steve to our team,” said Brian Ellacott, Independent Lead Director of the Company’s Board. “Steve is not only an experienced financial executive in the life science industry but also has a breadth of relevant NASDAQ listing and M&A experience that could prove to be invaluable as Profound executes the next stages of its growth strategy. I am confident that his expertise and guidance will be of significant benefit to the Company and its shareholders.”
About Steve Forte
Mr. Forte is a senior finance leader with broad experience in managing complex, large-scale finance environments. Most recently, he served as Chief Financial Officer at Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), which was acquired by Ipsen S.A. for approximately US$1.3 billion in April 2019. Before joining Clementia, Mr. Forte was CFO of Thinking Capital Financial Corporation, a leading financial technology firm, which he helped lead through rapid growth and ultimately to a successful sale of the company to Purpose Investments. Prior to that, Mr. Forte’s experience includes nearly a decade at Aptalis Pharma Inc., where he was responsible for the overall corporate controllership function of a multinational pharmaceutical company with approximately $700 million in annual revenue, six operating companies, five manufacturing sites and 40 subsidiaries. Mr. Forte led Aptalis’ preparations for a U.S. IPO prior to the successful sale of the company to Forest Labs for US$2.9 billion. Mr. Forte received his Bachelor of Commerce in Accountancy from Concordia University and is a CPA/CMA.
About Profound Medical Corp.
Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.
For more information: https://profoundmedical.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.